Abby Reed
Research Subjects
Abby Reed has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Abby Marquez
Revolution Medicines, Inc., Redwood City, California
63 shared publications - Adrian L. Gill
Revolution Medicines, Inc., Redwood City, California
63 shared publications - Aidan C.A. Tomlinson
Revolution Medicines, Inc., Redwood City, California
63 shared publications - Andrew J. Aguirre
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
63 shared publications - Benjamin J. Maldonato
Revolution Medicines, Inc., Redwood City, California
63 shared publications - Bianca J. Lee
Revolution Medicines, Inc., Redwood City, California
63 shared publications
Latest Publications
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
RMC-6236 is a potent noncovalent inhibitor of the GTP-bound state of multiple RAS variants in vitro. A, Chemical structure of RMC-6236. B, Biochemical potency of RMC-6236 for wild-type KRAS, NRAS, HRAS, and several oncogenic RAS variants. EC50 values shown for inhibition of RAS-RAF binding using recombinant proteins in vitro. Error bars indicate ± 95% CI. C, Immunoblot protein Western analyses of KRAS pathway targets in HPAC (KRASG12D/WT, PDAC) and Capan-2 (KRASG12V/WT, PDAC) cancer cells treated with RMC-6236 at the indicated concentrations and time points. D, RMC-6236 potency measured in the PRISM panel of cancer cell lines. Left, AUC difference between cell lines with and without a given gene mutation (x-axis) and the significance of the difference (y-axis). Points represent mutated genes. A negative AUC indicates increased sensitivity to RMC-6236 and positive AUC indicates resistance. Horizontal dashed line represents the P-value cutoff of 5 × 10−8. Vertical lines represent the absolute effect cutoff of 0.1. Right: AUC for KRAS mutant [glycine 12 depicted as KRASG12X (115 lines); all other KRAS mutations labeled KRASOther (42 lines)], NRAS mutant [glutamine 61 depicted as NRASQ61X (34 lines); all other NRAS mutations labeled as NRASOther (20 lines)], HRAS mutant, NF1 mutant, EGFR mutant, PTPN11 mutant, and BRAFV600E mutant cell lines are shown. Comparison of indicated groups was done by the Wilcoxon rank-sum test with continuity correction. (**, P < 0.01; ***, P < 0.001).
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
RMC-6236 is a potent noncovalent inhibitor of the GTP-bound state of multiple RAS variants in vitro. A, Chemical structure of RMC-6236. B, Biochemical potency of RMC-6236 for wild-type KRAS, NRAS, HRAS, and several oncogenic RAS variants. EC50 values shown for inhibition of RAS-RAF binding using recombinant proteins in vitro. Error bars indicate ± 95% CI. C, Immunoblot protein Western analyses of KRAS pathway targets in HPAC (KRASG12D/WT, PDAC) and Capan-2 (KRASG12V/WT, PDAC) cancer cells treated with RMC-6236 at the indicated concentrations and time points. D, RMC-6236 potency measured in the PRISM panel of cancer cell lines. Left, AUC difference between cell lines with and without a given gene mutation (x-axis) and the significance of the difference (y-axis). Points represent mutated genes. A negative AUC indicates increased sensitivity to RMC-6236 and positive AUC indicates resistance. Horizontal dashed line represents the P-value cutoff of 5 × 10−8. Vertical lines represent the absolute effect cutoff of 0.1. Right: AUC for KRAS mutant [glycine 12 depicted as KRASG12X (115 lines); all other KRAS mutations labeled KRASOther (42 lines)], NRAS mutant [glutamine 61 depicted as NRASQ61X (34 lines); all other NRAS mutations labeled as NRASOther (20 lines)], HRAS mutant, NF1 mutant, EGFR mutant, PTPN11 mutant, and BRAFV600E mutant cell lines are shown. Comparison of indicated groups was done by the Wilcoxon rank-sum test with continuity correction. (**, P < 0.01; ***, P < 0.001).
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S8 shows all parameter estimates for PK/Efficacy and PK/PD modeling.
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S8 shows all parameter estimates for PK/Efficacy and PK/PD modeling.
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Method from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
RMC-6236 synthetic route and detailed PK/PD/Efficacy Modeling method
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Method from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
RMC-6236 synthetic route and detailed PK/PD/Efficacy Modeling method
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
PK/PD/Efficacy modeling to predict clinically active dose range. A, Comparison of observed and predicted tumor growth data at multiple dose levels of RMC-6236 in the NCI-H441 xenograft tumor model. Tumor growth was predicted using the Simeoni tumor growth model. The dotted line indicates the initial average tumor volume. B, Comparison of observed and predicted tumor growth data at multiple dose levels of RMC-6236 in the Capan-2 xenograft tumor model. Tumor growth was predicted using the Simeoni tumor growth model. The dotted line indicates the initial average tumor volume. C, Comparison of observed vs. simulated PK and PD data at multiple dose levels of RMC-6236 in mice bearing NCI-H441 xenograft tumors. Single-dose data from all dose levels are presented from 0 to 24 hours, whereas repeat-dose data from 25 and 40 mg/kg repeat daily dosing is presented from 216 to 240 hours. Simulated blood and tumor PK data are indicated by the solid and dashed green and blue lines, respectively. Simulated PD data are indicated by the solid purple lines. Observed data are indicated by dots (blood PK and PD) or squares (tumor PK). The dotted line indicates the 10% expression level of DUSP6 mRNA as normalized to the vehicle control group. D, Predicted profiles of human whole blood and tumor PK as well as tumor PD at clinical dose levels at steady state. Blood PK and tumor PK are indicated by the solid and dashed green lines whereas tumor PD is indicated by the solid purple lines. Repeat dose data are presented from 336 to 360 hours after two weeks of simulated daily dosing. The dotted line indicates a 10% expression level of DUSP6 mRNA as normalized to the vehicle control group.
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
PK/PD/Efficacy modeling to predict clinically active dose range. A, Comparison of observed and predicted tumor growth data at multiple dose levels of RMC-6236 in the NCI-H441 xenograft tumor model. Tumor growth was predicted using the Simeoni tumor growth model. The dotted line indicates the initial average tumor volume. B, Comparison of observed and predicted tumor growth data at multiple dose levels of RMC-6236 in the Capan-2 xenograft tumor model. Tumor growth was predicted using the Simeoni tumor growth model. The dotted line indicates the initial average tumor volume. C, Comparison of observed vs. simulated PK and PD data at multiple dose levels of RMC-6236 in mice bearing NCI-H441 xenograft tumors. Single-dose data from all dose levels are presented from 0 to 24 hours, whereas repeat-dose data from 25 and 40 mg/kg repeat daily dosing is presented from 216 to 240 hours. Simulated blood and tumor PK data are indicated by the solid and dashed green and blue lines, respectively. Simulated PD data are indicated by the solid purple lines. Observed data are indicated by dots (blood PK and PD) or squares (tumor PK). The dotted line indicates the 10% expression level of DUSP6 mRNA as normalized to the vehicle control group. D, Predicted profiles of human whole blood and tumor PK as well as tumor PD at clinical dose levels at steady state. Blood PK and tumor PK are indicated by the solid and dashed green lines whereas tumor PD is indicated by the solid purple lines. Repeat dose data are presented from 336 to 360 hours after two weeks of simulated daily dosing. The dotted line indicates a 10% expression level of DUSP6 mRNA as normalized to the vehicle control group.
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Effects of RMC-6236 mediated pharmacologic modulation of RAS pathway signaling in tumor-bearing mice. A, PK/PD relationship between RMC-6236 concentration and inhibition of DUSP6 expression in Capan-2 (EC50 = 90 nmol/L and EC90 = 809 nmol/L), NCI-H441 (EC50 = 117 nmol/L and EC90 = 1,121 nmol/L), and HPAC (EC50 = 135 nmol/L and EC90 = 925 nmol/L) xenograft tumors. Subcutaneous xenograft tumors were treated with vehicle or RMC-6236 ranging from 0.3 to 100 mg/kg (Capan-2 and H441) or to 50 mg/kg (HPAC). B, PK/PD relationship between RMC-6236 concentration and inhibition of Dusp6 expression in ear skin (EC50 = 1,164 nmol/L and EC90 = 10,279 nmol/L) isolated from tumor-bearing BALB/c nude mice treated with vehicle or RMC-6236 ranging from 3 mg/kg to 100 mg/kg. A and B, Tumors and ear skin from tumor-bearing BALB/c nude mice were harvested at indicated time points (n = 3/timepoint/dose). A 3-parameter sigmoidal exposure–response model was fitted to the data to derive EC50 and EC90 values. Time points are represented by colors and doses are represented by symbol shapes. C–G, Histopathology of tumors and ear skin from the Capan-2 xenograft model collected at indicated time points post a single dose of vehicle control, RMC-6236 at 25 mg/kg or 7 consecutive daily doses of RMC-6236 at 25 mg/kg (n = 3–6/time point/dose). Staining of indicated markers in the tumor area or ear skin was quantified and compared with vehicle using one-way ANOVA followed by the Dunnett multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Representative images are shown at 200× magnification from samples closest to the mean of the respective groups. Scale bar, 50 µm.
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Effects of RMC-6236 mediated pharmacologic modulation of RAS pathway signaling in tumor-bearing mice. A, PK/PD relationship between RMC-6236 concentration and inhibition of DUSP6 expression in Capan-2 (EC50 = 90 nmol/L and EC90 = 809 nmol/L), NCI-H441 (EC50 = 117 nmol/L and EC90 = 1,121 nmol/L), and HPAC (EC50 = 135 nmol/L and EC90 = 925 nmol/L) xenograft tumors. Subcutaneous xenograft tumors were treated with vehicle or RMC-6236 ranging from 0.3 to 100 mg/kg (Capan-2 and H441) or to 50 mg/kg (HPAC). B, PK/PD relationship between RMC-6236 concentration and inhibition of Dusp6 expression in ear skin (EC50 = 1,164 nmol/L and EC90 = 10,279 nmol/L) isolated from tumor-bearing BALB/c nude mice treated with vehicle or RMC-6236 ranging from 3 mg/kg to 100 mg/kg. A and B, Tumors and ear skin from tumor-bearing BALB/c nude mice were harvested at indicated time points (n = 3/timepoint/dose). A 3-parameter sigmoidal exposure–response model was fitted to the data to derive EC50 and EC90 values. Time points are represented by colors and doses are represented by symbol shapes. C–G, Histopathology of tumors and ear skin from the Capan-2 xenograft model collected at indicated time points post a single dose of vehicle control, RMC-6236 at 25 mg/kg or 7 consecutive daily doses of RMC-6236 at 25 mg/kg (n = 3–6/time point/dose). Staining of indicated markers in the tumor area or ear skin was quantified and compared with vehicle using one-way ANOVA followed by the Dunnett multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Representative images are shown at 200× magnification from samples closest to the mean of the respective groups. Scale bar, 50 µm.
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S9 shows datasets used for PK/Efficacy and PK/PD modeling.
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S9 shows datasets used for PK/Efficacy and PK/PD modeling.
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Figure 1 shows RMC-6236 crystal structure in tri-complex, as well as biophysical and cellular potencies of RMC-6236 by genotype.Supplementary Figure 2 shows RMC-6236 demonstrates dose-dependent anti-tumor activities at tolerable doses; and pharmacodynamic effects on RAS signaling in NCI-H441 xenograft tumors as assessed by IHC, and in relatively refractory KP-4 and NCI-H2122 xenograft tumors as assessed by human DUSP6 mRNA expression in vivo.Supplementary Figure 3 shows genotype dependent response of RMC-6236 across NSCLC, PDAC and CRC; and potential modifiers to the durability of response of KRASG12C NSCLC models upon RMC-6236 treatment assessed by Kaplan-Meier analyses.Supplementary Figure 4 shows Efficacy of RMC-6236 on KrasG12C–driven autochthonous lung tumors harboring cis second-site mutations within KrasG12C (KrasG12C,H95D or KrasG12C,Y96C) and eCT26 (KrasG12D/G12D) syngeneic model in immunocompetent mice; anti-tumor immunity of RMC-6236; and in intracranially implanted NCI-H1373-Luc xenograft model on nude mice.Supplementary Figure 5 shows effects of RMC-6236 mediated pharmacological modulation in KP-4 xenograft tumors and normal colon tissues isolated from xenograft tumor bearing mice.Supplementary Figure 6 shows a graphical representation of the combined mouse PK-Efficacy and PK/PD model.
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Figure 1 shows RMC-6236 crystal structure in tri-complex, as well as biophysical and cellular potencies of RMC-6236 by genotype.Supplementary Figure 2 shows RMC-6236 demonstrates dose-dependent anti-tumor activities at tolerable doses; and pharmacodynamic effects on RAS signaling in NCI-H441 xenograft tumors as assessed by IHC, and in relatively refractory KP-4 and NCI-H2122 xenograft tumors as assessed by human DUSP6 mRNA expression in vivo.Supplementary Figure 3 shows genotype dependent response of RMC-6236 across NSCLC, PDAC and CRC; and potential modifiers to the durability of response of KRASG12C NSCLC models upon RMC-6236 treatment assessed by Kaplan-Meier analyses.Supplementary Figure 4 shows Efficacy of RMC-6236 on KrasG12C–driven autochthonous lung tumors harboring cis second-site mutations within KrasG12C (KrasG12C,H95D or KrasG12C,Y96C) and eCT26 (KrasG12D/G12D) syngeneic model in immunocompetent mice; anti-tumor immunity of RMC-6236; and in intracranially implanted NCI-H1373-Luc xenograft model on nude mice.Supplementary Figure 5 shows effects of RMC-6236 mediated pharmacological modulation in KP-4 xenograft tumors and normal colon tissues isolated from xenograft tumor bearing mice.Supplementary Figure 6 shows a graphical representation of the combined mouse PK-Efficacy and PK/PD model.
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S6 shows PK/PD data used to derive PK/PD relationship curves in Fig. 5 and Fig. S5.
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S6 shows PK/PD data used to derive PK/PD relationship curves in Fig. 5 and Fig. S5.
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S2 shows cell panel screening data with a panel of 78 cancer cell lines harboring mutant and wild-type RAS selected for screening at Crown Bioscience.
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S2 shows cell panel screening data with a panel of 78 cancer cell lines harboring mutant and wild-type RAS selected for screening at Crown Bioscience.
- Open Access
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S1 shows information on the PRISM cell set comprised of 845 cell lines representing more than 45 lineages.
- 5 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Supplementary Table S1 shows information on the PRISM cell set comprised of 845 cell lines representing more than 45 lineages.